The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Blue Ridge Cancer Care
Consulting or Advisory Role - Amgen
Speakers' Bureau - Bristol-Myers Squibb
Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer.
 
Jared Weiss
Stock and Other Ownership Interests - Nektar; Vesselon
Honoraria - Pfizer
Consulting or Advisory Role - abbvie; AstraZeneca; Azitra; Blueprint Medicines; Celgene; EMD Serono; G1 Therapeutics; Genentech; Inivata; Jounce Therapeutics; Lilly; Nanobiotix; Pfizer; Rakuten Medical
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Carefusion (Inst); Celgene (Inst); G1 Therapeutics (Inst); Immunicum (Inst); Loxo/Lilly (Inst); Merck (Inst); Pfizer (Inst)
 
Jerome Goldschmidt
No Relationships to Disclose
 
Andric Zoran
No Relationships to Disclose
 
Konstantin H. Dragnev
Research Funding - G1 Therapeutics (Inst); Io Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); PharmaMar (Inst); Roche/Genentech (Inst)
 
Yili Pritchett
Employment - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics
 
Shannon R. Morris
Employment - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics
 
Rajesh K. Malik
Employment - G1 Therapeutics
Leadership - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics
 
Davey B. Daniel
Research Funding - Abbvie (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); G1 Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Guardant Health (Inst); Immunomedics (Inst); Janssen Research & Development (Inst); Lilly (Inst); Merck (Inst); Merus NV (Inst); Novartis (Inst); Novartis (Inst)